Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 9/20 | 0.38 |
| ▸ | MIF | P14174 | 6/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | BACH1 | O14867 | 2/20 | 0.35 |
| ▸ | MAFK | O60675 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988586 | 0.86 | NAAA (0.52) | NAAATRPA1MIFBACH1MAFK | |
| SCHEMBL17416121 | 0.84 | TRPA1 (0.42) | NAAATRPA1MIFCYP2E1CYP2A6 | |
| SCHEMBL12697464 | 0.82 | NAAA (0.35) | NAAATRPA1MIFBACH1MAFK | |
| SCHEMBL18912053 | 0.78 | — | — | |
| SCHEMBL11726344 | 0.75 | NPSR1 (0.34) | NPSR1 | |
| SCHEMBL6668505 | 0.75 | NPSR1 (0.31) | NPSR1 | |
| SCHEMBL20274397 | 0.74 | — | — | |
| SCHEMBL1268079 | 0.74 | — | — | |
| SCHEMBL7501948 | 0.73 | CYP1A2 (0.39) | — | |
| SCHEMBL18911837 | 0.73 | NAAA (0.44) | NAAATRPA1MIFBACH1MAFK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199636-A1 | Inhibitors of RAD52 Recombination Protein and Methods Using Same | UNIV DREXEL (US) | 2024-06-20 | — | — | US | disclosed |
| EP-3383377-B1 | COMPOUNDS AND METHODS FOR INHIBITING PRODUCTION OF TRIMETHYLAMINE | PROCTER & GAMBLE (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20210040108-A1 | Inhibitors of RAD52 Recombination Protein and Methods Using Same | UNIV DREXEL (US) | 2021-02-11 | — | — | US | disclosed |
| US-10786479-B2 | Methods for inhibiting conversion of carnitine to trimethylamine (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2020-09-29 | — | — | US | disclosed |
| US-10780072-B2 | Methods for inhibiting conversion of choline to trimethylamine (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2020-09-22 | — | — | US | disclosed |
| US-10738061-B2 | Inhibitors of RAD52 recombination protein and methods using same | DREXEL UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-10442817-B2 | Inhibitors of RAD52 recombination protein and methods using same | DREXEL UNIVERSITY (US) | 2019-10-15 | — | — | US | disclosed |
| EP-3294732-B1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES INC (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-3294732-B1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES INC (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-3383377-A1 | COMPOUNDS AND METHODS FOR INHIBITING PRODUCTION OF TRIMETHYLAMINE | The Procter and Gamble Company (US) | 2018-10-10 | — | — | EP | disclosed |
| US-4596798-A | Herpes virus | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1986-06-24 | — | — | US | disclosed |
| US-4554242-A | Method for processing color photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1985-11-19 | — | — | US | disclosed |
| US-4493930-A | BACTERICIDES, ANTIMALARIA, AND ANTIGONORRHEA AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1985-01-15 | — | — | US | disclosed |
| US-4447427-A | PARTICULARLY GONORRHEA OR MALARIA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1984-05-08 | — | — | US | disclosed |
| US-4401670-A | Method for treating gonorrhea infections with 2-acetyl- and 2-propionylpyridine thiosemicarbazones | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1983-08-30 | — | — | US | disclosed |
| US-4385055-A | 2-Acetyl-and 2-propionylpyridine thiosemicarbazones as antimalarials | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1983-05-24 | — | — | US | disclosed |
| US-4317776-A | BACTERICIDES, ANTIMALARIAL, TREATMENT OF GONORRHEA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1982-03-02 | — | — | US | disclosed |
| US-4169899-A | PENICILLAMINE COMPOUNDS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1979-10-02 | — | — | US | disclosed |
| US-3991065-A | ANTIULCER AGENTS, CHEMICAL INTERMEDIATES | JOHN WYETH & BROTHER LIMITED (EN) | 1976-11-09 | — | — | US | disclosed |
| US-3932318-A | COPOLYMERS WITH ISOCYANATES, CRYOGENIC POLYMERIZATION, NONFLAMMABLE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040108-A1 | Inhibitors of RAD52 Recombination Protein and Methods Using Same | RAD52, RAD50, MRE11 | NAAA 2652/4885TRPA1 4789/4885MIF 2586/4885 |
| US-10738061-B2 | Inhibitors of RAD52 recombination protein and methods using same | RAD52, RAD50, MRE11 | NAAA 2652/4885TRPA1 4789/4885MIF 2586/4885 |
| US-20240199636-A1 | Inhibitors of RAD52 Recombination Protein and Methods Using Same | RAD52, RAD50, MRE11 | NAAA 2652/4885TRPA1 4789/4885MIF 2586/4885 |
| US-10780072-B2 | Methods for inhibiting conversion of choline to trimethylamine (TMA) | HNMT, BHMT, PNMT | NAAA 67/4885TRPA1 2682/4885MIF 245/4885 |
| US-10442817-B2 | Inhibitors of RAD52 recombination protein and methods using same | RAD52, RAD50, MRE11 | NAAA 2652/4885TRPA1 4789/4885MIF 2586/4885 |
| US-10786479-B2 | Methods for inhibiting conversion of carnitine to trimethylamine (TMA) | CRAT, CPT1A, CPT1B | NAAA 279/4885TRPA1 1835/4885MIF 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.